ARS Pharmaceuticals Inc. reported its financial results for the first quarter of 2025, highlighting total revenues of $8.0 million. This figure includes $7.8 million in net product revenue from sales of **_neffy_** in the U.S. and $0.2 million in collaboration revenue from ALK-Abelló A/S $(ALK)$. The company reported a net loss of $33.9 million for the quarter. Research and development expenses amounted to $3.0 million, primarily associated with the ongoing clinical and development efforts for **_neffy_**. Selling, general, and administrative expenses were $41.1 million, largely due to personnel-related and sales and marketing expenses tied to the commercialization of **_neffy_**. ARS Pharmaceuticals also provided an update on the U.S. commercial launch of **_neffy®_** (epinephrine nasal spray), the first FDA-approved and European Commission-approved needle-free epinephrine treatment for Type I allergic reactions, including anaphylaxis. The product has been prescribed by over 5,000 physicians, demonstrating considerable demand. The company forecasts that its current financial position, with cash, cash equivalents, and short-term investments totaling $275.7 million, will support its operating plans for at least the next three years.